Related Experiment Video

Updated: May 15, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

RA16-Modified DNA Tetrahedra: Targeted Delivery and Inhibition in Non-Small Cell Lung Cancer

Kunyao Xu1,2,3, Hao Wang1, Yongping Jiang2,3

  • 1Beijing University of Chemical Technology, Beijing 100029, China.

ACS Applied Bio Materials
|May 14, 2025
PubMed

Insights

Researchers developed novel RA16-functionalized DNA nanomaterials to improve non-small cell lung cancer (NSCLC) therapy. These stable nanoparticles enhance drug delivery and significantly boost therapeutic efficacy, offering a promising new treatment platform for NSCLC patients.

Area of Science:

  • Biotechnology
  • Nanomedicine
  • Oncology

Background:

  • Lung cancer, particularly non-small cell lung cancer (NSCLC), has a low survival rate, necessitating innovative therapeutic strategies.
  • RNA aptamer RA16 shows promise for NSCLC targeting but suffers from poor in vivo stability, limiting its clinical use.

Purpose of the Study:

  • To develop and evaluate RA16-functionalized DNA nanomaterials for enhanced NSCLC targeted therapy.
  • To improve the stability and drug-loading capacity of the RA16 aptamer for clinical applications.

Main Methods:

  • Fabrication of RA16-functionalized tetrahedral DNA (TD) nanostructures for enhanced stability and drug delivery.
  • In vitro characterization of RA16-TD nanoparticles for biocompatibility, stability, and drug-loading efficiency.
  • In vivo evaluation in H460 xenograft mouse models to assess tumor accumulation and therapeutic efficacy of RA16-TD loaded with Epirubicin.

Main Results:

  • RA16-TD nanoparticles demonstrated excellent biocompatibility, stability, and high drug-loading capacity.
  • RA16-TD significantly enhanced cell binding and internalization (10-fold) compared to free RA16.
  • In vivo studies showed 2.43-fold higher tumor accumulation of RA16-TD and a superior tumor inhibition rate (77.8%) with Epirubicin-loaded RA16-TD compared to controls.

Conclusions:

  • RA16-functionalized DNA nanomaterials represent a stable and effective platform for targeted NSCLC therapy.
  • This nanodrug delivery system overcomes the limitations of free aptamers, improving therapeutic outcomes.
  • The developed platform holds significant potential for advancing clinical applications in NSCLC treatment.
Keywords:
DNA tetrahedronaptamernon-small cell lung cancertargeted therapytumor inhibition

More Related Videos

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.0K
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K